Skip to content
Core Fusion Peptides

Peptides studied for tissue repair, tendon/ligament healing, gut mucosa, wound healing and angiogenesis.

RECOVERY & TISSUE REPAIR / COLOPHON

About This Reference Desk

A citation-anchored crosswalk of the repair-blend literature, reading shared peptides across blends. Not a vendor. Not a clinic. Not medical advice.

What Core Fusion Peptides is

Core Fusion Peptides is a crosswalk across the published research on three multi-peptide blends studied for recovery and tissue repair: Wolverine (BPC-157 + TB-500), KLOW (KPV + GHK-Cu + BPC-157 + TB-500), and GLOW (GHK-Cu + BPC-157 + TB-500), with Wolverine as the lead. It exists to make a scattered, technically demanding, and frequently oversimplified literature legible — to tell a reader, in plain language and with citations, what each blend's constituent peptides were actually studied for, in which species, and how far that evidence reaches.

The organizing idea is the fusion: several of these blends share constituent peptides, so their literatures overlap. BPC-157 and TB-500 appear in all three; GHK-Cu links KLOW and GLOW; KPV is exclusive to KLOW. Reading the blends together reveals both the shared foundation and the specific arms that distinguish them. Each blend has its own page; a comparison page lines them up side by side; and a single shared references list aggregates every source across all three.

A critical structural note

One fact runs through every page on this desk and belongs in the colophon too: none of the three blends has been tested in a controlled study. Every efficacy and mechanism claim for Wolverine, KLOW or GLOW is an extrapolation from the single-component literature of its constituent peptides, which is itself overwhelmingly preclinical.

This site does not paper over that gap. Where the combination rationale is mechanistic reasoning rather than direct blend evidence, we say so explicitly. Where a constituent's most persuasive data come from a full-length parent protein rather than the marketed fragment (as with TB-500 and thymosin beta-4), we flag it. Where human data exist for a constituent (as with GHK-Cu's topical dermatology work), we report them — and note that topical evidence does not establish injectable blend safety. The aim is an accurate map of what is known, not a case for any blend.

How it is compiled

Three principles govern what appears on this site.

First, everything is anchored to the peer-reviewed literature. Each research claim carries a numbered citation — PubMed-indexed journal articles and reviews, with DOIs or PubMed / PMC links — collected on the references page. Where a finding comes from a review, the review is cited as such.

Second, the evidence is reported at its true strength. Doses are described in the species and route in which they were studied — for example, "studied at 10 micrograms per kilogram in rats" — never scaled to humans or offered as a recommendation. Where evidence is preclinical, single-lab, or rests on a parent molecule rather than the marketed compound, the page says so plainly.

Third, community-use reports, where present, are labeled anecdotal. KLOW and GLOW have rich community write-up traditions; those accounts are summarized on the relevant pages, explicitly labeled as anecdotal and not clinical evidence, and never used to substitute for or inflate the peer-reviewed record.

What it is not

Core Fusion Peptides is not a store, a clinic, or a source of medical advice. It sells, supplies, sources, and brokers nothing — no peptide, no research chemical — and holds no affiliate or referral tie to any vendor. No clinicians work here; it diagnoses nothing, prescribes nothing, and recommends no dose, schedule, or route for any person.

The peptides discussed here are research compounds. None of the three blends is an approved medicine; TB-500 is explicitly prohibited in sport. Readers interested in any condition described in the underlying research should consult a licensed clinician operating within their own jurisdiction, working with regulated, evidence-based options.